Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial.

Attard, Gerhardt; Sydes, Matthew R; Mason, Malcolm D; Clarke, Noel W; Aebersold, Daniel; de Bono, Johann S; Dearnaley, David P; Parker, Chris C; Ritchie, Alastair W S; Russell, J Martin; Thalmann, George; Cassoly, Estelle; Millman, Robin; Matheson, David; Schiavone, Francesca; Spears, Melissa R; Parmar, Mahesh K B; James, Nicholas D (2014). Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial. European urology, 66(5), pp. 799-802. Elsevier 10.1016/j.eururo.2014.05.038

[img]
Preview
Text
1-s2.0-S030228381400520X-main.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (933kB) | Preview

There are compelling reasons to study the addition of both enzalutamide and abiraterone, in combination, to standard-of-care for hormone-naïve prostate cancer. Through a protocol amendment, this will be assessed in the STAMPEDE trial, with overall survival as primary outcome measure.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Urology
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Radiation Oncology

UniBE Contributor:

Aebersold, Daniel and Thalmann, George

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0302-2838

Publisher:

Elsevier

Language:

English

Submitter:

Beatrice Scheidegger

Date Deposited:

10 Mar 2015 16:33

Last Modified:

10 Mar 2015 16:33

Publisher DOI:

10.1016/j.eururo.2014.05.038

PubMed ID:

24985962

BORIS DOI:

10.7892/boris.61607

URI:

https://boris.unibe.ch/id/eprint/61607

Actions (login required)

Edit item Edit item
Provide Feedback